Krebs Biochemicals & Industries Ltd (KREBSBIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524518 | NSE: KREBSBIO | Pharmaceuticals & Drugs | Small Cap

Krebs Biochem.&Inds Share Price

69 5.06 7.91%
as on 05-Dec'25 12:17

Krebs Biochemicals & Industries Ltd (KREBSBIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524518 | NSE: KREBSBIO | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Krebs Biochem.&Inds

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Krebs Biochemicals & Industries stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
137.9 Cr.
52-wk low:
63.6
52-wk high:
115.5

Is Krebs Biochemicals & Industries Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Krebs Biochem.&Inds: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Krebs Biochemicals & Industries Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -25.4%-27.1%-29%-35.4%-57%-40.3%-57.4%-28.6%-19%-29.9%-
Value Creation
Index
-2.8-2.9NANANANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1.33.533.847.833.453.759.752.150.443.327
Sales YoY Gr.-173.6%856.9%41.4%-30.1%60.7%11.2%-12.7%-3.3%-14.1%-
Adj EPS -12.9-11.4-12.4-12.1-16-14.5-20.7-11.5-9.2-12.5-12.7
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 6.91-12.5-8.6-18.1-23.9-34.8-46.1-55.3-67.8-73.2
Adj Net
Profit
-17.4-16.2-17.6-20.1-28.9-28.4-44.5-24.7-19.7-27-27
Cash Flow from Ops. -15.3-11.2-6.23.9-35.5-14.6-17.2-24.72.4-7.9-
Debt/CF from Ops. -2-4.2-9.113.7-1.9-7.6-8.3-7.481.9-26.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 47.8%5.3%-10.2%-14.1%
Adj EPS NANANANA
BVPS-228.9%NANANA
Share Price -4.5% -6.9% -15.1% -33.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-111.2-224.2216.4125.314783.775.628.31820.418.1
Op. Profit
Mgn %
-961.7-226.6-22.2-20.4-55.5-32.7-56.9-30.3-17.3-34.7-55.1
Net Profit
Mgn %
-1349.5-460.1-52.2-42.1-86.4-52.8-74.6-47.4-39.1-62.4-101
Debt to
Equity
3.332.2-3.2-3.7-2-2.4-1.9-1.8-1.6-1.5-
Working Cap
Days
7,1061,48820115824317921823117919593
Cash Conv.
Cycle
1,149366-17-32-11210-11-36-892

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Krebs Biochemicals & Industries Ltd.

Standalone Consolidated
TTM EPS (₹) -12.7 -
TTM Sales (₹ Cr.) 27.2 -
BVPS (₹.) -73.2 -
Reserves (₹ Cr.) -179 -
P/BV -0.87 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 63.55 / 115.50
All Time Low / High (₹) 9.10 / 293.59
Market Cap (₹ Cr.) 138
Equity (₹ Cr.) 21.6
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Krebs Biochem.&Inds:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Krebs Biochem.&Inds - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Krebs Biochem.&Inds

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales143448335460525043
Operating Expenses 14124158527194685958
Manufacturing Costs421316172633233333
Material Costs0113231626412676
Employee Cost 661114151515161616
Other Costs 3344445333
Operating Profit -12-8-8-10-19-18-34-16-9-15
Operating Profit Margin (%) -961.0%-226.0%-22.2%-20.4%-55.5%-32.7%-56.9%-30.3%-17.3%-34.7%
Other Income 1000011101
Interest 1356665356
Depreciation 4444556777
Exceptional Items 0-0-10000000
Profit Before Tax -16-16-18-20-29-28-45-25-20-27
Tax 0000000000
Profit After Tax -16-16-18-20-29-28-45-25-20-27
PAT Margin (%) -1,265.5%-454.0%-52.8%-41.9%-86.4%-52.8%-74.6%-47.4%-39.1%-62.2%
Adjusted EPS (₹)-12.1-11.3-12.5-12.0-16.0-14.5-20.7-11.5-9.2-12.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 91-18-14-33-47-75-99-119-146
Share Capital 13141417182022222222
Reserves -4-12-32-31-51-67-97-121-141-168
Minority Interest0000000000
Debt2543525066111143183193212
Long Term Debt2543525066101133173184161
Short Term Debt000001010101051
Trade Payables12111821232138151918
Others Liabilities 69677485787584768585
Total Liabilities 116122126142134159190175178169

Fixed Assets

Gross Block213227230234243261288303312314
Accumulated Depreciation120124129133138143149156163168
Net Fixed Assets 93102101101105118139147150146
CWIP 114434128423
Investments 0000000000
Inventories6512915172612106
Trade Receivables0203001120
Cash Equivalents 00017010000
Others Assets 799891216111414
Total Assets 116122126142134159190175178169

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -15-11-64-35-15-17-252-8
PBT -17-16-17-20-29-28-45-25-20-27
Adjustment 31161091211101212
Changes in Working Capital -1-2914-16216-10107
Tax Paid 000000000-0
Cash Flow From Investing Activity -4-5-3-4-10-23-23-13-8-5
Capex 4-13-4-5-9-18-27-15-90
Net Investments 0000000000
Others -8921-2-5432-5
Cash Flow From Financing Activity 131691729384037613
Net Proceeds from Shares 194025191013000
Net Proceeds from Borrowing 8179-215330010-22
Interest Paid 000-6-6-6-5-3-5-6
Dividend Paid 0000000000
Others -14-5010-03240-041
Net Cash Flow -6-0017-171-1-000

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-683.34-296.7N/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)-25.38-27.13N/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0.010.030.270.360.240.370.340.290.290.25
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days528410121724598
Inventory Days1,43657393791311071291317967
Payable Days03,5594143105073052643789491,219

Krebs Biochemicals & Industries Ltd Stock News

Krebs Biochemicals & Industries Ltd FAQs

The current trading price of Krebs Biochem.&Inds on 05-Dec-2025 12:17 is ₹69.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Krebs Biochem.&Inds stood at ₹137.9.
The latest P/E ratio of Krebs Biochem.&Inds as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Krebs Biochem.&Inds as of 04-Dec-2025 is -0.87.
The 52-week high of Krebs Biochem.&Inds is ₹115.5 and the 52-week low is ₹63.55.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Krebs Biochem.&Inds is ₹27.21 ( Cr.) .

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.

KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.

The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.

KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Product range of the company includes:

Bulk activities

Synthetic

  • Lavastatin
  • Simvastatin
  • I -Ephedrochiloride
  • l - Ephedrine Sulphate
  • l - Ephedrine Base (Liquid)
  • d - Pseudoephedrine Hydrochloride
  • d - Pseudoephedrine Sulphate
  • d - Pseudoephedrine Base
  • dl - Ephedrine Base
  • n - Methyl Ephedrine
  • d - Ephedrine Bitartarate
  • Vitamin C
  • Vitamin C (Coated)

Herbal

  • Calcium Sennosides - 20% & 60%
  • Garcinia Combogia Powdered Extract
  • Capsaicin - 50/100

Intermediates

  • Crude Lovastatin
  • Simvastatin Ammonium Salt

Products in pipeline

  • Pravastatin Sodium

Achievements/ recognition:

  • ISO 9002 in November 2001 
  • EDQM July 2003 
  • USFDA in November 2003 
  • ISO 9001 – 2000 in March 2004 
  • WHO GMP certification in November 2002 and renewed in March 2005
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×